<DOC>
	<DOCNO>NCT01288001</DOCNO>
	<brief_summary>A pilot , open , randomise , control , add-on study evaluate duration efficacy one intra articular injection sodium hyaluronate 2.0 % patient painful osteoarthritis knee</brief_summary>
	<brief_title>Study Evaluating Duration Efficacy One Intra Articular Injection Sodium Hyaluronate 2.0 % Patients With Painful Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Patients gender 40 70 year age ; 2 . Primary tibiofemoral osteoarthritis knee accord American College Rheumatology criterion ; 3 . Pain â‰¥ 4 10 point scale least two five subscores WOMAC Section A baseline ; 4 . Radiologically ascertain grade II III severity knee osteoarthritis KellgrenLawrence scale ; 5 . Having give sign informed consent . 1 . Secondary knee osteoarthritis , include : septic arthritis ; inflammatory joint disease ; gout ; recurrent episodes pseudogout ; Paget 's disease bone ; articular fracture ; ochronosis ; acromegaly ; haemochromatosis ; Wilson 's disease ; primary osteochondromatosis . 2 . Clinical sign acute flare ( pain , warm , erythema , effusion signal knee ) baseline ; 3 . Axial deviation &gt; 15 degree valgus varus stand Xray ; 4 . Clinically significant mediolateral anteroposterior instability ; 5 . Rapid destructive arthritis , evolve arthritis require surgery within coming year ; 6 . Significant injury signal knee within 6 month prior baseline ; 7 . Complete loss range motion ; 8 . Painful knee condition osteoarthritis ( e.g. , Sudeck 's atrophy , intraarticular neoplasm , villonodular synovitis ) ; 9 . Necrosis one femur condyles ; 10 . History evidence gout , chondrocalcinosis ; 11 . Peripheral neuropathy ; 12 . Concomitant rheumatic disease : fibromyalgia ; rheumatoid arthritis ; collagen disease ; psoriatic arthritis seronegative spondylarthropathies ( e.g. , ankylose spondylitis ) ; metabolic crystalinduced arthropathy ; osteopathy . 13 . Contraindications intraarticular injection accord investigator 's judgement ( e.g. , local infection injection site , generalise infection possible bacteraemia ) ; 14 . Skin disease area injection ; 15 . Severe coagulopathy , ongoing anticoagulation therapy ; 16 . Accompanying OA hip sufficient severity interfere assessment signal knee ; 17 . Disease spine , hip low extremity joint sufficient degree affect assessment signal knee ; 18 . Poor general health interfere compliance assessment ; 19 . Concomitant disease/ailment knee OA require regular use patient 's normal analgesic medicine ; 20 . Initiation chronic treatment antihistaminics , glucocorticoid , antidepressant tranquilisers , within less 3 month prior baseline ; 21 . Use assistive device cane ( walk stick ) ; 22 . Surgery signal knee arthroscopy ; 23 . Arthroscopy signal knee within one year prior baseline ; 24 . Treatment symptomatic slow act drug OA ( SYSADOA , i.e. , chondroitin sulfate , diacerein , glucosamine , piascledine ) , unless patient stable dose least 4 month prior baseline ; 25 . Intraarticular depocorticosteroid injection signal knee within 3 month prior baseline ; 26 . Intraarticular SH injection signal knee within 6 month prior baseline ; 27 . Ascertained hypersensitivity product use study ( SH , paracetamol , diclofenac , omeprazole ) similar compound ; 28 . Pregnant lactate female ; 29 . Female childbearing potential without adequate contraceptive method ; 30 . Participation drug clinical trial within 3 month prior screen ; 31 . Patients , judgement investigator , comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>